摘要
背景:复发是克罗恩病(CD)继发的手术切除术后常见的事件。 一年后90%的患者发生内镜下炎症反应,定义为术后内镜下复发(PER)。 PER先于临床复发并且由于随后的肠损伤而需要再次手术。 因此,预防手术后控制炎症对疾病控制至关重要。 目标:审查关于CD中PER的数据,并演示手术后管理的算法。 结果:在CD手术后没有固定的策略来预防复发。 有几个风险因素必须考虑考虑指导医生在这种情况下选择最佳的治疗药物和策略。 在这篇综述中,作者详细描述了基于风险因素的分层,主要用于预防复发的治疗剂,并讨论了CD术后管理的几种选择。 结论:CD手术切除后不推荐固定策略。 因此,根据几个条件和变量,强调每个患者对个性化方法的需求。
关键词: 克罗恩氏病,复发,术后护理,炎症,术后内镜复发,治疗。
图形摘要
Current Drug Targets
Title:Postoperative Approach for Crohn's Disease: The Right Therapy to the Right Patient
Volume: 19 Issue: 7
关键词: 克罗恩氏病,复发,术后护理,炎症,术后内镜复发,治疗。
摘要: Background: Recurrence is a common event after surgical resections secondary to Crohn's disease (CD). Endoscopic signs of inflammation, defined as postoperative endoscopic recurrence (PER) occur in up to 90% of the patients after one year. PER precedes clinical recurrence and further need for reoperations due to consequent bowel damage. Therefore, controlling inflammation after surgery in a preventive way is essential for disease control.
Objective: to review data regarding PER in CD, and demonstrate algorithms for its management after surgery.
Results: There is no fixed strategy to prevent recurrence after surgery in CD. There are several risk factors that must be taken into consideration to guide physicians to choose the best therapeutic agents and strategies in this scenario. In this review, the authors describe in details the stratification based on risk factors, the therapeutic agents mostly used to prevent recurrence and discuss the several options for the postoperative management in CD.
Conclusions: No fixed strategy is recommended after surgical resections in CD. Thus, the need for a personalized approach for each patient is emphasized, in accordance with several conditions and variables.
Export Options
About this article
Cite this article as:
Postoperative Approach for Crohn's Disease: The Right Therapy to the Right Patient, Current Drug Targets 2018; 19 (7) . https://dx.doi.org/10.2174/1389450116666151102094922
DOI https://dx.doi.org/10.2174/1389450116666151102094922 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome
Current Pharmaceutical Design Editorial [Hot Topic: The Human Microbiome - A Therapeutic Target for Prevention and Treatment of Chronic Disease (Executive Editor: Kieran Tuohy)]
Current Pharmaceutical Design Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Current Pharmaceutical Design Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer?
Current Cancer Drug Targets Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model
Current Pharmaceutical Biotechnology Protein-based Strategies of Molecular Therapy in Allergy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Realizing the Potential of Health-Promoting Rosehips from Dogroses (Rosa sect. Caninae)
Current Bioactive Compounds Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Multiple Sclerosis: Pathogenesis and Treatment
Current Neuropharmacology Biomedical Applications of Natural Polymers for Drug Delivery
Current Organic Chemistry Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology Immunoregulation Through 1,25-Dihydroxyvitamin D 3 and its Analogs
Current Drug Targets - Inflammation & Allergy Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design Patent Selections
Recent Patents on Biotechnology Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Conjugation Strategies for Colonic Delivery and its Application in Colorectal Cancer Therapy
Current Drug Metabolism Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Current Pharmaceutical Design Roles of miRNA in the Initiation and Development of Colorectal Carcinoma
Current Pharmaceutical Design